P53 expression in stage I squamous cell lung cancer

Judit Moldvay, J. Strausz, Márta Egerváry, László Agócs, József Bocsi, Z. Schaff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

P53 expression was studied using immunohistochemistry in patients (n=94) with pathologic stage I squamous cell lung cancer treated surgically between 1991-1992. The overall p53 positivity ratio was 48/94. 83 of the cases proved to be suitable for follow-up analysis carried out in November, 1995. 46/83 were p53 positive, and 25/46 patients were alive at the time of analysis. The patients who died (21/46) had a mean survival time of 17.5 months. In p53 negative cases (37/83), however, 29/37 patients were still alive at the time of follow-up, and 8/37 had died with a mean survival time of 23.1 months. A significant correlation could be found between p53 immunopositivity and reduced survival time (p=0.0125). Interestingly, out of 83 cases analyzed histologic evidence of tuberculous scar tissue was present in 9 tumors with a p53 positivity ratio of only 1/9. When flow cytometry was used to examine tumor samples from all subgroups mentioned above (n=32), no correlation was found between the p53 immunopositivity or the prognosis and the DNA content of tumor tissues. Our results suggest that in the early stage of squamous cell lung cancer the p53 positivity may be an indicator of a more aggressive tumor behavior and a shortened survival time.

Original languageEnglish
Pages (from-to)8-13
Number of pages6
JournalPathology and Oncology Research
Volume4
Issue number1
Publication statusPublished - 1998

Fingerprint

Squamous Cell Neoplasms
Lung Neoplasms
Neoplasms
Survival Rate
Survival
Cicatrix
Flow Cytometry
Immunohistochemistry
DNA

Keywords

  • Flow cytometry
  • Immunohistochemistry
  • Lung cancer
  • P53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Moldvay, J., Strausz, J., Egerváry, M., Agócs, L., Bocsi, J., & Schaff, Z. (1998). P53 expression in stage I squamous cell lung cancer. Pathology and Oncology Research, 4(1), 8-13.

P53 expression in stage I squamous cell lung cancer. / Moldvay, Judit; Strausz, J.; Egerváry, Márta; Agócs, László; Bocsi, József; Schaff, Z.

In: Pathology and Oncology Research, Vol. 4, No. 1, 1998, p. 8-13.

Research output: Contribution to journalArticle

Moldvay, J, Strausz, J, Egerváry, M, Agócs, L, Bocsi, J & Schaff, Z 1998, 'P53 expression in stage I squamous cell lung cancer', Pathology and Oncology Research, vol. 4, no. 1, pp. 8-13.
Moldvay, Judit ; Strausz, J. ; Egerváry, Márta ; Agócs, László ; Bocsi, József ; Schaff, Z. / P53 expression in stage I squamous cell lung cancer. In: Pathology and Oncology Research. 1998 ; Vol. 4, No. 1. pp. 8-13.
@article{9a0f8e5d2e724d9fbb6bf6dce53769c5,
title = "P53 expression in stage I squamous cell lung cancer",
abstract = "P53 expression was studied using immunohistochemistry in patients (n=94) with pathologic stage I squamous cell lung cancer treated surgically between 1991-1992. The overall p53 positivity ratio was 48/94. 83 of the cases proved to be suitable for follow-up analysis carried out in November, 1995. 46/83 were p53 positive, and 25/46 patients were alive at the time of analysis. The patients who died (21/46) had a mean survival time of 17.5 months. In p53 negative cases (37/83), however, 29/37 patients were still alive at the time of follow-up, and 8/37 had died with a mean survival time of 23.1 months. A significant correlation could be found between p53 immunopositivity and reduced survival time (p=0.0125). Interestingly, out of 83 cases analyzed histologic evidence of tuberculous scar tissue was present in 9 tumors with a p53 positivity ratio of only 1/9. When flow cytometry was used to examine tumor samples from all subgroups mentioned above (n=32), no correlation was found between the p53 immunopositivity or the prognosis and the DNA content of tumor tissues. Our results suggest that in the early stage of squamous cell lung cancer the p53 positivity may be an indicator of a more aggressive tumor behavior and a shortened survival time.",
keywords = "Flow cytometry, Immunohistochemistry, Lung cancer, P53",
author = "Judit Moldvay and J. Strausz and M{\'a}rta Egerv{\'a}ry and L{\'a}szl{\'o} Ag{\'o}cs and J{\'o}zsef Bocsi and Z. Schaff",
year = "1998",
language = "English",
volume = "4",
pages = "8--13",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - P53 expression in stage I squamous cell lung cancer

AU - Moldvay, Judit

AU - Strausz, J.

AU - Egerváry, Márta

AU - Agócs, László

AU - Bocsi, József

AU - Schaff, Z.

PY - 1998

Y1 - 1998

N2 - P53 expression was studied using immunohistochemistry in patients (n=94) with pathologic stage I squamous cell lung cancer treated surgically between 1991-1992. The overall p53 positivity ratio was 48/94. 83 of the cases proved to be suitable for follow-up analysis carried out in November, 1995. 46/83 were p53 positive, and 25/46 patients were alive at the time of analysis. The patients who died (21/46) had a mean survival time of 17.5 months. In p53 negative cases (37/83), however, 29/37 patients were still alive at the time of follow-up, and 8/37 had died with a mean survival time of 23.1 months. A significant correlation could be found between p53 immunopositivity and reduced survival time (p=0.0125). Interestingly, out of 83 cases analyzed histologic evidence of tuberculous scar tissue was present in 9 tumors with a p53 positivity ratio of only 1/9. When flow cytometry was used to examine tumor samples from all subgroups mentioned above (n=32), no correlation was found between the p53 immunopositivity or the prognosis and the DNA content of tumor tissues. Our results suggest that in the early stage of squamous cell lung cancer the p53 positivity may be an indicator of a more aggressive tumor behavior and a shortened survival time.

AB - P53 expression was studied using immunohistochemistry in patients (n=94) with pathologic stage I squamous cell lung cancer treated surgically between 1991-1992. The overall p53 positivity ratio was 48/94. 83 of the cases proved to be suitable for follow-up analysis carried out in November, 1995. 46/83 were p53 positive, and 25/46 patients were alive at the time of analysis. The patients who died (21/46) had a mean survival time of 17.5 months. In p53 negative cases (37/83), however, 29/37 patients were still alive at the time of follow-up, and 8/37 had died with a mean survival time of 23.1 months. A significant correlation could be found between p53 immunopositivity and reduced survival time (p=0.0125). Interestingly, out of 83 cases analyzed histologic evidence of tuberculous scar tissue was present in 9 tumors with a p53 positivity ratio of only 1/9. When flow cytometry was used to examine tumor samples from all subgroups mentioned above (n=32), no correlation was found between the p53 immunopositivity or the prognosis and the DNA content of tumor tissues. Our results suggest that in the early stage of squamous cell lung cancer the p53 positivity may be an indicator of a more aggressive tumor behavior and a shortened survival time.

KW - Flow cytometry

KW - Immunohistochemistry

KW - Lung cancer

KW - P53

UR - http://www.scopus.com/inward/record.url?scp=0031861328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031861328&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 8

EP - 13

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -